Clinical trial Recruiting at 1 site Observational Ages 18 to 64

Brain connectivity changes in glioma patients during treatment

Official title: Functional Reorganization and Connectivity in Glioma Patients During the Therapeutic Trajectory

Run by Johannes Kepler University of Linz · NCT07612917 · Data updated 2026-11-12

Researchers will observe how glioma treatment affects brain connectivity and function using repeated MRI to see if brain areas and their connections adapt over time.

Quick facts

Study typeObservational
Ages18 Years to 64 Years
SexAll
Enrollment20 (estimated)
SponsorJohannes Kepler University of Linz
Academic / other
Locations1 site (Linz, Upper Austria)
StatusRecruiting
StartedMay 1, 2026
Main results expectedSeptember 2029
Study endsDecember 2029
Registry record updatedAugust 13, 2026
Trial IDNCT07612917 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-64 with diffuse gliomas (WHO grade 2-4) who can undergo baseline and follow-up fMRI and neurocognitive testing with informed consent.

Probably not a fit

Patients who cannot complete serial MRI or neurocognitive assessments, or who have contraindications to MRI, may not benefit from the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study involving adults with diffuse gliomas (WHO grades 2-4) who undergo repeated functional MRI and neurocognitive assessments as part of their care. The goal is to map how key brain regions and their white matter connections reorganize during treatment, shedding light on neuroplasticity in the context of glioma therapy. Imaging and cognitive data will be analyzed over the course of treatment to identify patterns of change and potential predictors of adaptation. No experimental interventions are described; the study relies on standard imaging and assessments available to participants. Results may inform understanding of brain resilience and guide future patient management.

Why it matters

Potential benefit: Findings could help clinicians anticipate brain changes during treatment and tailor supportive care to preserve function.

How similar studies have gone: Prior imaging studies in glioma have shown brain network changes during treatment, supporting feasibility of this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with diffuse gliomas (WHO grade 2-4).
* Age \>18 years and \<65 years.
* Written participant information and informed consent provided and signed.
* Signed informed consent for functional magnetic resonance imaging (fMRI).

Exclusion Criteria:

* Age \<18 years or \>65 years.
* Pregnancy.
* Contraindications to MRI, including but not limited to:

  * Active medical implants (e.g., pain pump, defibrillator, cardiac pacemaker),
  * Orthodontic braces,
  * Metallic tattoos,
  * Non-removable piercings,
  * Known metallic foreign bodies,
  * Claustrophobia.
* Cerebral metastases from secondary (non-primary) tumors.
* Absence of baseline BOLD functional MRI and/or baseline neurocognitive assessment.
* Failure to provide written participant information and informed consent.
* Karnofsky Performance Status (KPS) \<60, unless feasibility of clinical-psychological testing and BOLD fMRI is confirmed by the investigator in consultation with clinical psychology, radiology staff, and the patient.

Where it's running

  • Kepler University Hospital
    Linz, Upper Austria, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.